Abstract:Key PointsProstate cancer pathogenesis is dependent on signalling through the steroid nuclear hormone androgen receptor (AR), which is activated after binding of the androgen ligand testosterone or dihydrotestosterone. Ligand-bound AR translocates to the nucleus, where it serves to induce or repress gene expression through binding to chromatin at cis androgen response elements.Medical castration to substantially deplete serum testosterone is the mainstay of therapy for advanced prostate cancer that recurs following surgical removal of the prostate (prostatectomy) or radiotherapy. However, castration therapy is not curative, and patients will eventually progress to lethal castration-resistant prostate cancer (CRPC).Despite a castrate level of testosterone, CRPC almost uniformly remains dependent on AR signalling. Next-generation hormonal therapies for prostate cancer, abiraterone and enzalutamide, are now in widespread clinical use; abiraterone attacks AR signalling through inhibition of extra-gonadal androgen biosynthesis and enzalutamide interferes directly with androgen binding to AR.Resistance mechanisms to these drugs have been identified that result in restoration of AR signalling through gain-of-function AR mutations, upregulation of constitutively active AR splice variants or increased intratumoural androgen biosynthesis. Another resistance mechanism bypasses AR by switching to the related glucocorticoid receptor (GR) to maintain transcriptional regulation of a subset of the same genes.At resistance, a subset of patients are now presenting with low or no AR in their tumours, suggesting that evolution to complex genomic states completely independently of AR could increasingly become a cause for concern.Comprehensive analyses of late-stage CRPC are uncovering multiple genetic lesions in this patient cohort that indicate that it may eventually be possible to stratify patients based on the genomic profile of their cancer. These efforts will aid in clinical trial design and facilitate the use of rationally designed combination strategies to improve patient outcomes.

Therapy resistance in prostate cancer: mechanism, signaling and reversal strategies

Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling.

Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation

From Therapy Resistance to Targeted Therapies in Prostate Cancer

Epigenetic mechanism of therapeutic resistance and potential of epigenetic therapeutics in chemorefractory prostate cancer

Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer

Overcoming Chemoresistance and Radio resistance in Prostate Cancer: The Emergent Role of Non-Coding RNAs

Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope

Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets

Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer

Current Treatment Modalities Targeting Tumor Microenvironment in Castration-Resistant Prostate Cancer

Current therapy and drug resistance in metastatic castration-resistant prostate cancer

Uncovering the Secrets of Prostate Cancer's Radiotherapy Resistance: Advances in Mechanism Research.

Treatment-induced stemness and lineage plasticity in driving prostate cancer therapy resistance

Recent advances and future perspectives in the therapeutics of prostate cancer

Insights into the Biological Properties of Prostate Cancer Stem Cells: Implications for Cancer Progression and Therapy

Timing of treatment shapes the path to androgen receptor signaling inhibitor resistance in prostate cancer

Lipid Metabolism and Endocrine Resistance in Prostate Cancer, and New Opportunities for Therapy

Combinatorial approaches of nanotherapeutics for inflammatory pathway targeted therapy of prostate cancer

Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications

Dysregulated Signalling Pathways Driving Anticancer Drug Resistance